The price of Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) shares last traded on Wall Street rose 0.48% to $62.25.
RYTM stock price is now 15.49% away from the 50-day moving average and 35.40% away from the 200-day moving average. The market capitalization of the company currently stands at $3.83B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $70, Guggenheim recently initiated with Buy rating for Rhythm Pharmaceuticals Inc (NASDAQ: RYTM). On September 18, 2024, H.C. Wainwright recently initiated its ‘Buy’ rating on the stock quoting a target price of $64, while ‘JMP Securities’ rates the stock as ‘Mkt Outperform’
In other news, Lee Jennifer Kayden, EVP, Head of North America sold 66,861 shares of the company’s stock on Nov 11 ’24. The stock was sold for $4,434,882 at an average price of $66.33. Upon completion of the transaction, the EVP, Head of North America now directly owns 972 shares in the company, valued at $60507.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 11 ’24, Chief Technical Officer Shulman Joseph sold 13,281 shares of the business’s stock. A total of $882,341 was realized by selling the stock at an average price of $66.44. A total of 10.82% of the company’s stock is owned by insiders.
During the past 12 months, Rhythm Pharmaceuticals Inc has had a low of $31.52 and a high of $68.58. As of last week, the company has a debt-to-equity ratio of 22.73, a current ratio of 3.49, and a quick ratio of 3.34. The fifty day moving average price for RYTM is $53.728 and a two-hundred day moving average price translates $45.9075 for the stock.
The latest earnings results from Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) was released for 2024-09-30. The net profit margin was -232.41% and return on equity was -248.12% for RYTM. The company reported revenue of $33.25 million for the quarter, compared to $22.5 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 47.76 percent.
